Melanoma
Researchers from the United States, Australia and Germany detail new studies and findings in the area of melanoma
Published in Vaccine Weekly, October 18th, 2006
Study 1: Immune response to at least two melanoma peptides improves long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells
According to a study from the United States, "Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells."
"The DC vaccine was loaded with four melanoma...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-10-18)
More Articles from Vaccine Weekly
- Measles Vaccine
One-dose measles vaccine may not provide long-term protection - Monkeypox Vaccine
Subunit recombinant vaccine protects against monkeypox - Pediatrics
Vaccine against ear infections may be in clinical trials by 2007 - Tuberculosis Vaccine
Influenza virus vectors expressing the Mycobacterium tuberculosis protein protect against tuberculosis - Alzheimer Disease Vaccine
Papillomavirus-like particles act as platform for Abeta immunization - Angiogenesis
Stem cell-like glioma cells promote tumor angiogenesis via growth factor - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
